Skip to main content
. 2021 Oct 1;8:734735. doi: 10.3389/fnut.2021.734735

Figure 3.

Figure 3

Kaplan–Meier survival curves examing the relationship between progressive-disease albumin and progressive disease overall survival of patients with NSCLC treated with first-line (A) targeted therapy or (B) immunotherapy-based therapy.